Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ).
ResMed Inc.’s Chief Financial Officer, Brett Sandercock, reported changes in his beneficial ownership of the company’s common stock. On August 1, 2025, Sandercock acquired 2,000 shares through stock options and disposed of 3,000 shares, as part of a pre-established trading plan under Rule 10b5-1. These transactions reflect a routine adjustment in his holdings, with implications for his personal investment strategy rather than the company’s operational or market positioning.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$41.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. operates in the healthcare industry, focusing on the development and manufacturing of products for the treatment of sleep disorders and respiratory care. The company is known for its innovative solutions in sleep apnea therapy and other chronic respiratory conditions, catering to a global market.
Average Trading Volume: 869,315
Technical Sentiment Signal: Buy
Current Market Cap: A$64.19B
See more data about RMD stock on TipRanks’ Stock Analysis page.